Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18783556 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | July 2024 | October 2025 | Abandon | 15 | 2 | 0 | No | Yes |
| 18783777 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | July 2024 | September 2025 | Abandon | 14 | 2 | 1 | No | No |
| 18422878 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | January 2024 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18507435 | MACROMOLECULES | November 2023 | February 2026 | Abandon | 27 | 1 | 1 | No | No |
| 18386971 | PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASES | November 2023 | June 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18366130 | TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS | August 2023 | March 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18338970 | ULINASTATIN POLYPEPTIDES | June 2023 | March 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18328029 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | June 2023 | November 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18203411 | HEMOSTATIC COMPOSITIONS | May 2023 | March 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18195078 | COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS, AND USES THEREOF | May 2023 | October 2024 | Abandon | 17 | 2 | 1 | No | No |
| 18309359 | MINIMALLY TOXIC PRODRUGS | April 2023 | December 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18167010 | TREATMENT OF FRAGILE X SYNDROME | February 2023 | October 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18165695 | THERAPEUTIC MOLECULES | February 2023 | April 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18081969 | ZINC-CHARGED PEPTIDES FOR THE TREATMENT OF CANCER AND ALZHEIMER'S DISEASE | December 2022 | April 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18057898 | PEPTIDES DERIVED FROM FIBRONECTIN WITH IMPROVED BIOACTIVITY AND REDUCED SUSCEPTIBILITY TO NEUTROPHIL ELASTASE DEGRADATION | November 2022 | September 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17986922 | ZWITTERIONIC POLYPEPTIDE AND DERIVATIVE THEREOF AND NANODRUG BASED THEREON | November 2022 | September 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17979531 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | November 2022 | February 2026 | Abandon | 39 | 3 | 1 | Yes | No |
| 17976603 | METHODS AND COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | October 2022 | February 2026 | Abandon | 39 | 3 | 1 | Yes | Yes |
| 17972348 | CLEAVABLE LINKER COMPOSITIONS AND METHODS | October 2022 | September 2024 | Abandon | 23 | 1 | 1 | Yes | No |
| 17799552 | POLYPEPTIDE DRUG FOR PREVENTING AND/OR TREATING NEUROBLASTOMA AND USE THEREOF | August 2022 | March 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17814363 | CATIONIC CELL PENETRATING PEPTIDES AND THE USE THEREOF | July 2022 | September 2023 | Allow | 14 | 1 | 2 | Yes | No |
| 17869348 | DRUG FOR INHIBITING ADIPOSE CELL DIFFERENTIATION AND INSULIN RESISTANCE | July 2022 | September 2025 | Abandon | 38 | 5 | 1 | No | No |
| 17811302 | OLIGOPEPTIDE WITH ANTI-INFLAMMATORY ACTIVITY, PREPARATION METHOD, AND APPLICATION THEREOF | July 2022 | April 2023 | Allow | 9 | 1 | 0 | No | No |
| 17855002 | METHODS FOR INCREASING INTRACELLULAR ACTIVITY OF HSP70 | June 2022 | December 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17843866 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | June 2022 | March 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17838028 | CYCLIC COMPOUNDS FOR TREATING CANCER | June 2022 | January 2026 | Allow | 43 | 4 | 1 | No | No |
| 17749713 | TGFBR2-BASED CHIMERIC PROTEINS | May 2022 | October 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17749969 | Alpha-sheet Polypeptides and Their Use | May 2022 | November 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17746474 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | May 2022 | May 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17737008 | iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | May 2022 | February 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17735371 | ALBUMIN-BINDING PRODRUG FOR PREVENTING OR TREATING CANCER AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | May 2022 | January 2025 | Abandon | 33 | 4 | 1 | No | No |
| 17728582 | ERYTHROPOIETIN COMPOSITIONS AND METHODS OF USE | April 2022 | July 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17703523 | REDIRECTING DEATH-INDUCING SIGNAL COMPLEX (DISC) BY MODIFYING DEATH RECEPTOR AGONIST TO INDUCE CELL DEATH FOR CANCER TREATMENT | March 2022 | February 2025 | Abandon | 35 | 3 | 1 | No | No |
| 17698185 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | March 2022 | October 2023 | Allow | 19 | 1 | 1 | Yes | No |
| 17686748 | PEPTIDES AND PEPTIDE CONJUGATES FOR TREATING MENTAL DISORDERS | March 2022 | March 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17586807 | LIPOSOMES AND USES THEREOF | January 2022 | June 2023 | Allow | 16 | 0 | 1 | No | No |
| 17631019 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17559430 | NEUREGULIN-4 COMPOUNDS AND METHODS OF USE | December 2021 | June 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17551493 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | December 2021 | March 2025 | Abandon | 39 | 4 | 1 | No | No |
| 17549369 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 | December 2021 | April 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17617709 | An improved process for the preparation of Plecanatide | December 2021 | January 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17544773 | ZINC-CHARGED PEPTIDES FOR THE TREATMENT OF CANCER AND ALZHEIMER'S DISEASE | December 2021 | March 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17543213 | NANOSPHERES OF SEC14-LIKE PROTEINS AND COGNATE LIGANDS | December 2021 | January 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17531538 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | November 2021 | February 2023 | Allow | 15 | 0 | 1 | No | No |
| 17526861 | FOOD ADDITIVE INCLUDING MANNAN OLIGOSACCHARIDES TO ENHANCE ANIMAL PERFORMANCE AND METHOD OF USING THE SAME | November 2021 | May 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17506876 | Therapeutic molecules | October 2021 | November 2022 | Allow | 13 | 1 | 1 | Yes | No |
| 17485171 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | September 2021 | December 2024 | Abandon | 39 | 3 | 1 | Yes | No |
| 17475545 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | September 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17469491 | Peptide Inhibitors Targeting Methyltransfer Mechanism of SARS-CoV-2 | September 2021 | December 2025 | Allow | 52 | 5 | 1 | Yes | No |
| 17436424 | PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | September 2021 | September 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17459842 | PEPTIDE INHIBITORS OF NF KAPPA B AND USE THEREOF IN TREATMENT OF COVID-19 AND INFLAMMATORY DISEASES | August 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17430037 | A MEMBRANE-BOUND FIT-1 DECOY AND USES THEREOF | August 2021 | July 2025 | Abandon | 48 | 2 | 1 | Yes | No |
| 17398500 | CLEAVABLE LINKER COMPOSITIONS AND METHODS | August 2021 | July 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17383675 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | July 2021 | June 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17350497 | DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION | June 2021 | April 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17341465 | POLYPEPTIDES WITH PHASE TRANSITION, TRIBLOCK POLYPEPTIDES OF THE POLYPEPTIDE-CALMODULIN-POLYPEPTIDE WITH MULTI-STIMULI RESPONSIVENESS, HYDROGEL OF THE TRIBLOCK POLYPEPTIDES, AND ITS USES | June 2021 | November 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17296679 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | May 2021 | September 2024 | Allow | 39 | 1 | 1 | No | No |
| 17329225 | INTRANASAL ADMINISTRATION | May 2021 | August 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17327863 | COMBINATION THERAPY INCLUDING SAPC-DOPS FOR THE TREATMENT OF PANCREATIC CANCER | May 2021 | September 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17296369 | LPL-GPIHBP1 FUSION POLYPEPTIDES | May 2021 | January 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17309373 | COMPOUND, USE, PHARMACEUTICAL COMPOSITION, METHOD OF DIAGNOSIS, METHOD OF TREATMENT, AND METHOD OF TRANSPORTATION AND/OR INTERNALIZATION OF A COMPOUND INTO EUKARYOTIC CELLS | May 2021 | November 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17320907 | NANOPARTICLE COMPOSITIONS AND USES THEREOF | May 2021 | July 2025 | Abandon | 51 | 3 | 1 | No | No |
| 17320760 | STORAGE STABLE SOMATOSTATIN-DOPAMINE CHIMERIC COMPOUNDS AND SALT FORMS THEREOF | May 2021 | March 2022 | Abandon | 10 | 1 | 0 | No | No |
| 17226996 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | April 2021 | May 2025 | Abandon | 49 | 2 | 2 | No | No |
| 17212951 | METHODS FOR REGULATING TRANSCRIPTION OF MULTIPLE GENES AND EXPRESSION OF MULTIPLE TARGETS | March 2021 | March 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17207222 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | March 2021 | April 2024 | Abandon | 37 | 5 | 0 | No | Yes |
| 17184745 | HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE | February 2021 | September 2025 | Abandon | 55 | 5 | 1 | No | No |
| 17141876 | Methods and Compositions for Treating a Disease Condition in a Subject | January 2021 | February 2025 | Abandon | 50 | 4 | 2 | No | No |
| 17129303 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | December 2020 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17254617 | SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | December 2020 | August 2025 | Abandon | 56 | 4 | 1 | No | No |
| 17102427 | SELECTIVE MCL-1 BINDING PEPTIDES | November 2020 | April 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17083409 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 AND LOW MEAN ARTERIAL PRESSURE | October 2020 | January 2023 | Abandon | 26 | 3 | 0 | No | No |
| 17047258 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS | October 2020 | November 2023 | Abandon | 37 | 2 | 1 | Yes | No |
| 17031583 | PEPTIDE PHARMACEUTICALS | September 2020 | August 2023 | Abandon | 35 | 3 | 1 | No | No |
| 17028400 | TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS | September 2020 | December 2023 | Abandon | 39 | 2 | 1 | No | No |
| 17016168 | PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE | September 2020 | September 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16970894 | GEL-FORMING POLYPEPTIDES | August 2020 | May 2025 | Abandon | 57 | 2 | 2 | No | No |
| 16993814 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | August 2020 | July 2021 | Abandon | 11 | 1 | 0 | No | No |
| 16988398 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | August 2020 | September 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16986706 | COMPOSITION AND METHOD FOR TREATING A PATIENT HAVING LIVER CIRRHOSIS | August 2020 | November 2022 | Abandon | 27 | 3 | 1 | Yes | Yes |
| 16933908 | GDF11 VARIANTS AND USES THEREOF | July 2020 | March 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16961345 | TREATMENT OF FRAGILE X SYNDROME | July 2020 | February 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16925464 | MACROMOLECULES | July 2020 | January 2024 | Abandon | 42 | 2 | 1 | No | No |
| 16858505 | PROTECTIVE METALLOTHIONEIN ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES | April 2020 | March 2023 | Abandon | 35 | 3 | 1 | No | No |
| 16754944 | COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS | April 2020 | September 2023 | Abandon | 41 | 4 | 1 | No | No |
| 16838348 | ACTIVATABLE MEMBRANE-INTERACTING PEPTIDES AND METHODS OF USE | April 2020 | January 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16835787 | NEUREGULIN-4 COMPOUNDS AND METHODS OF USE | March 2020 | September 2021 | Allow | 18 | 2 | 1 | No | No |
| 16832634 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | March 2020 | August 2022 | Allow | 28 | 5 | 0 | Yes | No |
| 16828674 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | March 2020 | November 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16828681 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | March 2020 | January 2023 | Abandon | 34 | 2 | 0 | No | No |
| 16826208 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | March 2020 | February 2026 | Abandon | 60 | 6 | 1 | No | Yes |
| 16817490 | THERAPEUTIC AGENT PREPARATIONS AND METHODS FOR DRUG DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | March 2020 | May 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16500177 | MULTIBLOCK COPOLYPEPTIDES OF ELASTIN-BASED POLYPEPTIDES AND MUSSEL FOOT PROTEINS WITH STIMULI-RESPONSIVENESS AND SURFACE-ADHESIVE, METHODS OF PREPARING THEREOF AND USE THEREOF | March 2020 | June 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16798141 | PURIFICATION OF POLYPEPTIDES USING DUAL STAGE TANGENTIAL-FLOW ULTRAFILTRATION | February 2020 | October 2022 | Abandon | 31 | 2 | 0 | No | No |
| 16641013 | MODIFIED HEAT SHOCK PROTEINS | February 2020 | June 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16640468 | E-POLY-L-LYSINE DERIVATIVES HAVING FUNCTIONAL GROUP FOR CLICK CHEMISTRY, METHOD FOR PRODUCING THE SAME, AND USE THEREOF | February 2020 | March 2026 | Abandon | 60 | 6 | 1 | Yes | No |
| 16751581 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | January 2020 | June 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16751668 | MINIMALLY TOXIC PRODRUGS | January 2020 | May 2023 | Abandon | 39 | 3 | 0 | Yes | No |
| 16632684 | CLUSTERIN FOR USE IN THE TREATMENT OF THROMBOTIC MICROANGIOPATHIES | January 2020 | August 2024 | Allow | 55 | 6 | 1 | Yes | Yes |
| 16631315 | STABILIZED ANTI-MICROBIAL PEPTIDES FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS | January 2020 | January 2022 | Allow | 24 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, JIA-HAI.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, JIA-HAI works in Art Unit 1658 and has examined 248 patent applications in our dataset. With an allowance rate of 44.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner LEE, JIA-HAI's allowance rate of 44.4% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, JIA-HAI receive 2.48 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEE, JIA-HAI is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +34.5% benefit to allowance rate for applications examined by LEE, JIA-HAI. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 7.7% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.6% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 73.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 86.3% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.